Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.

Autor:	Rizk EM; Department of Medicine, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA., Gartrell RD; Department of Medicine, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA., Barker LW; College of Physicians and Surgeons, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA., Esancy CL; Department of Medicine, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA., Finkel GG; College of Physicians and Surgeons, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA., Bordbar DD; College of Physicians and Surgeons, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA., Saenger YM; Department of Medicine, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA. Electronic address: yms4@cumc.columbia.edu.
Jazyk:	angličtina
Zdroj:	Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2019 Apr; Vol. 33 (2), pp. 291-299. Date of Electronic Publication: 2019 Jan 17.
DOI:	10.1016/j.hoc.2018.12.005
Abstrakt:	Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 + tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key. (Copyright © 2018 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu